ClinicalTrials.gov
ClinicalTrials.gov Menu

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy (ADI-PEG 20)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01287585
Recruitment Status : Completed
First Posted : February 1, 2011
Last Update Posted : September 18, 2018
Sponsor:
Information provided by (Responsible Party):
Polaris Group

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : July 2015
  Actual Study Completion Date : July 2015
  Certification/Extension First Submitted : August 10, 2016
Publications:
Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen C-J, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro GM, Harris WP, Chen Z, Hubner R, Meyer T, Bomalaski JS, Lin CC, Chao Y, Chen LZ. 2016. Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 34, 2016 (suppl; abstr 4017).